← Back to Search

Unknown

BMS-963272 for Non-alcoholic Fatty Liver Disease

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, day 15, day 29, day 57, and day 84
Awards & highlights

Summary

This trial is testing a new drug called BMS-963272 to see if it is safe and well-tolerated in people with severe liver disease. The study focuses on those with nonalcoholic fatty liver disease (NAFLD) and a high chance of advanced fibrosis.

Eligible Conditions
  • Non-alcoholic Fatty Liver Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, day 15, day 29, day 57, and day 84
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1, day 15, day 29, day 57, and day 84 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events (AEs)
Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry test
Incidence of clinically significant changes in clinical laboratory results: Coagulation tests
+12 more
Secondary outcome measures
Pharmacokinetic (PK) sampling: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])
Pharmacokinetic (PK) sampling: Maximum observed plasma concentration (Cmax)
Pharmacokinetic (PK) sampling: Time to maximum observed plasma concentration (Tmax)
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Active Treatment (BMS-963272) Dosing Regimen 2Experimental Treatment1 Intervention
Group II: Active Treatment (BMS-963272) Dosing Regimen 1Experimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-963272
2019
Completed Phase 1
~160

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,652 Previous Clinical Trials
4,130,740 Total Patients Enrolled
9 Trials studying Non-alcoholic Fatty Liver Disease
895 Patients Enrolled for Non-alcoholic Fatty Liver Disease
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top